-DOCSTART- -X- O
Drug-resistant -X- _ O
Mycobacterium -X- _ O
tuberculosis -X- _ O
( -X- _ O
M. -X- _ O
tuberculosis -X- _ O
) -X- _ O
has -X- _ O
become -X- _ O
an -X- _ O
increasingly -X- _ O
serious -X- _ O
public -X- _ O
health -X- _ O
problem -X- _ O
and -X- _ O
has -X- _ O
complicated -X- _ O
tuberculosis -X- _ O
( -X- _ O
TB -X- _ O
) -X- _ O
treatment. -X- _ O
Levofloxacin -X- _ B-Intervention
( -X- _ I-Intervention
LOF -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
an -X- _ O
ideal -X- _ O
anti-tuberculosis -X- _ O
drug -X- _ O
in -X- _ O
clinical -X- _ O
applications. -X- _ O
However -X- _ O
, -X- _ O
the -X- _ O
detailed -X- _ O
molecular -X- _ O
mechanisms -X- _ O
of -X- _ O
LOF-resistant -X- _ O
M. -X- _ O
tuberculosis -X- _ O
in -X- _ O
TB -X- _ O
treatment -X- _ O
have -X- _ O
not -X- _ O
been -X- _ O
revealed. -X- _ O
Our -X- _ O
study -X- _ O
performed -X- _ O
transcriptome -X- _ B-Comparison
and -X- _ I-Comparison
methylome -X- _ I-Comparison
sequencing -X- _ I-Comparison
to -X- _ O
investigate -X- _ O
the -X- _ O
potential -X- _ O
biological -X- _ O
characteristics -X- _ O
of -X- _ O
LOF -X- _ O
resistance -X- _ O
in -X- _ O
M. -X- _ B-Patient
tuberculosis -X- _ I-Patient
H37Rv. -X- _ I-Patient
In -X- _ O
the -X- _ O
transcriptome -X- _ O
analysis -X- _ O
, -X- _ O
953 -X- _ B-Outcome
differentially -X- _ I-Outcome
expressed -X- _ I-Outcome
genes -X- _ I-Outcome
( -X- _ I-Outcome
DEGs -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ O
identified -X- _ O
; -X- _ O
514 -X- _ O
and -X- _ O
439 -X- _ O
DEGs -X- _ O
were -X- _ O
significantly -X- _ O
downregulated -X- _ O
and -X- _ O
upregulated -X- _ O
in -X- _ O
the -X- _ O
LOF-resistant -X- _ O
group -X- _ O
and -X- _ O
control -X- _ O
group -X- _ O
, -X- _ O
respectively. -X- _ O
The -X- _ O
KEGG -X- _ O
pathway -X- _ O
analysis -X- _ O
revealed -X- _ O
that -X- _ O
97 -X- _ B-Outcome
pathways -X- _ I-Outcome
were -X- _ I-Outcome
enriched -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
study. -X- _ I-Outcome
In -X- _ O
the -X- _ O
methylome -X- _ O
analysis -X- _ O
, -X- _ O
239 -X- _ B-Outcome
differentially -X- _ I-Outcome
methylated -X- _ I-Outcome
genes -X- _ I-Outcome
( -X- _ I-Outcome
DMGs -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ O
identified -X- _ O
; -X- _ O
150 -X- _ O
and -X- _ O
89 -X- _ O
DMGs -X- _ O
were -X- _ O
hypomethylated -X- _ O
and -X- _ O
hypermethylated -X- _ O
in -X- _ O
the -X- _ O
LOF-resistant -X- _ O
group -X- _ O
and -X- _ O
control -X- _ O
group -X- _ O
, -X- _ O
respectively. -X- _ O
The -X- _ O
KEGG -X- _ O
pathway -X- _ O
analysis -X- _ O
revealed -X- _ O
that -X- _ O
74 -X- _ B-Outcome
pathways -X- _ I-Outcome
were -X- _ I-Outcome
enriched -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
study. -X- _ I-Outcome
The -X- _ O
overlap -X- _ O
study -X- _ O
suggested -X- _ O
that -X- _ O
25 -X- _ B-Outcome
genes -X- _ I-Outcome
were -X- _ I-Outcome
obtained. -X- _ I-Outcome
It -X- _ O
was -X- _ O
notable -X- _ O
that -X- _ O
nine -X- _ O
genes -X- _ O
expressed -X- _ O
downregulated -X- _ O
mRNA -X- _ O
and -X- _ O
upregulated -X- _ O
methylated -X- _ O
levels -X- _ O
, -X- _ O
including -X- _ O
pgi -X- _ B-Outcome
, -X- _ I-Outcome
fadE4 -X- _ I-Outcome
, -X- _ I-Outcome
php -X- _ I-Outcome
, -X- _ I-Outcome
cyp132 -X- _ I-Outcome
, -X- _ I-Outcome
pckA -X- _ I-Outcome
, -X- _ I-Outcome
rpmB1 -X- _ I-Outcome
, -X- _ I-Outcome
pfkB -X- _ I-Outcome
, -X- _ I-Outcome
acg -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
ctpF -X- _ I-Outcome
, -X- _ O
especially -X- _ O
cyp132 -X- _ O
, -X- _ O
pckA -X- _ O
, -X- _ O
and -X- _ O
pfkB -X- _ O
, -X- _ O
which -X- _ O
were -X- _ O
vital -X- _ O
in -X- _ O
LOF-resistant -X- _ O
M. -X- _ B-Patient
tuberculosis -X- _ I-Patient
H37Rv. -X- _ I-Patient
The -X- _ O
overlapping -X- _ O
genes -X- _ O
between -X- _ O
transcriptome -X- _ O
and -X- _ O
methylome -X- _ O
could -X- _ O
be -X- _ O
essential -X- _ O
for -X- _ O
studying -X- _ O
the -X- _ O
molecular -X- _ O
mechanisms -X- _ O
of -X- _ O
LOF-resistant -X- _ O
M. -X- _ B-Patient
tuberculosis -X- _ I-Patient
H37Rv. -X- _ I-Patient
These -X- _ O
results -X- _ O
may -X- _ O
provide -X- _ O
informative -X- _ O
evidence -X- _ O
for -X- _ O
TB -X- _ O
treatment -X- _ O
with -X- _ O
LOF. -X- _ O
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
10.1007 -X- _ O
/ -X- _ O
s00239-019-09926-z -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

